Small Cell Lung Cancer | Meet The Professor: Optimizing the Management of Small Cell Lung Cancer — Part 2

Featuring perspectives from Dr Carl Gay, including the following topics:

• Introduction: Journal Club with Carl M Gay, MD, PhD (0:00)
• Case: A woman in her early 60s with extensive-stage small cell lung cancer (ES-SCLC) and a small residual lung mass after carboplatin/etoposide/atezolizumab — Kapisthalam (KS) Kumar, MD (19:15)
• Case: A woman and heavy smoker in her early 70s who develops widespread ES-SCLC after chemotherapy/radiation therapy for limited-stage SCLC — Neil Morganstein, MD (24:24)
• Case: A man in his mid 60s with ES-SCLC and disease progression after carboplatin/etoposide/atezolizumab with central nervous system metastases (FGFR1 gain, tumor mutational burden 11 mut/Mb) who receives lurbinectedin/radiation to the brain — Adam R Miller, MD (38:36)
• Case: A man in his early 60s with progressive ES-SCLC s/p carboplatin/atezolizumab on lurbinectedin with dose adjustment — Rohit Gosain, MD (47:38)
• Case: A woman and current smoker in her early 70s with ES-SCLC who receives dose-attenuated chemoimmunotherapy due to multiple comorbidities — Minesh Dinubhai Patel, MD (58:09)

CME information and select publications